Last reviewed · How we verify
CRx-197
CRx-197 is a small molecule that modulates the TRPV1 receptor.
CRx-197 is a small molecule that modulates the TRPV1 receptor. Used for Chronic pain.
At a glance
| Generic name | CRx-197 |
|---|---|
| Sponsor | Zalicus |
| Drug class | TRPV1 receptor modulator |
| Target | TRPV1 |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 2 |
Mechanism of action
CRx-197 works by binding to the TRPV1 receptor, which is involved in pain signaling. This binding leads to a decrease in pain perception, making it a potential treatment for various pain conditions.
Approved indications
- Chronic pain
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- A Single-Center Exploratory Study to Assess the Activity of CRx-197-002 in Plaque Psoriasis (PHASE2)
- A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CRx-197 CI brief — competitive landscape report
- CRx-197 updates RSS · CI watch RSS
- Zalicus portfolio CI